Navigation Links
DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study
Date:9/25/2007

SOMERSET, N.J., Sept. 25 /PRNewswire-FirstCall/ -- DOV Pharmaceutical, Inc. ("DOV", or the "Company") (OTCBB and Pink Sheets: DOVP) announced today additional Phase Ib results for DOV 21,947, its lead triple reuptake inhibitor ("TRIP") for the treatment of depression and obesity. A preliminary analysis of the study results demonstrated that DOV 21,947 was safe and well-tolerated at the doses examined, and produced a statistically significant reduction in plasma triglyceride levels, as described more fully below. Further analyses of these data demonstrate that DOV 21,947 significantly reduces body weight and Body Mass Index ("BMI") in drug-compliant subjects compared to placebo. The Company intends to initiate a Phase II study of DOV 21,947 for the treatment of depression in the first quarter of 2008.

This double-blind, placebo-controlled Phase Ib study enrolled 46 male and female volunteers. Following a one-week placebo run-in, subjects received either escalating daily doses of 50 mg, 100 mg and 150 mg of DOV 21,947 (31 subjects) or placebo (15 subjects), for a total of eight weeks. Those subjects with detectable blood levels of DOV 21,947 or its principal metabolite during at least three of four bimonthly visits (approximately 70% of the drug-treated subjects) were classified as drug compliant.

At the end of this eight-week study, the mean difference in body weight change from baseline between the drug-compliant and placebo groups was 4.6 pounds (p<0.006). Furthermore, following a one-week wash-out period, this highly significant difference in body weight change between the groups was reduced by almost 50%, indicating a reversible, drug-related effect. Statistical results similar to those for the body weight reduction were obtained for the BMI. The mean difference in BMI change from baseline between the drug-compliant and placebo groups was 0.75 kg/m2 (p<0.005), with a reversible drug-related effect at the end of the one-week wash-out period.


'/>"/>
SOURCE DOV Pharmaceutical, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
4. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
5. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
6. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
7. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
8. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
9. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
10. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
11. Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of Docetaxel Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... CHAPEL HILL, N.C. , July 31, 2015 ... to product success in the biopharmaceutical market. Patients ... the process of selecting and switching therapies. This ... and is pushing marketers, efforts toward patient-focused marketing. ... to patient engagement, marketers have learned it,s important ...
(Date:7/31/2015)... July 31, 2015  In today,s ever-changing marketplace, call ... increasingly mobile, increasingly connected, and increasingly impatient with slow ... customer interaction channels and tools is driving call centers ... According to research by benchmarking firm, ... (OTC) segment in a call center study realize the ...
(Date:7/31/2015)... 31, 2015  Seeger Weiss LLP is reporting that on ... warning letter to C.R. Bard, the manufacturer of Inferior ... to correct violations the agency found at two of Bard,s ... the FDA cited them during Inspectional Observations that occurred on ... Tempe, AZ , location and on October 6, ...
Breaking Medicine Technology:Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3
... 20, 2011 Sevocity, a division of Conceptual MindWorks, ... selected by CITIA-SC as a preferred electronic health record ... Sevocity is the leading true Internet or cloud-based EHR. ... and customizable electronic health record system with low start-up ...
... 2011 Concentric Medical, Inc., the global leader in ... announced the launch of the expanded family of Merci ... 2.0 Soft and V 3.0 Soft, through recent Ichihen ... are now approved and reimbursed in Japan.  The Merci ...
Cached Medicine Technology:Sevocity® Named Preferred EHR Vendor by CITIA-SC, South Carolina's Health IT Regional Extension Center (REC) 2Concentric Medical Launches Full Family of Merci Retrievers® in Japan 2Concentric Medical Launches Full Family of Merci Retrievers® in Japan 3
(Date:7/31/2015)... ... 2015 , ... The Mount Sinai Health System will work with Columbia Care ... related, experimental treatments. The collaboration moves into the next phase with the recent decision ... five state licenses to produce and dispense medical marijuana. , Mount Sinai and ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... BioViva USA, ... the way we treat aging diseases. , BioViva announces it has begun a ... patients with Alzheimer’s Disease (AD) and find a cure. MaxLife will grant 100% of ...
(Date:7/31/2015)... Toledo, Ohio (PRWEB) , ... July 31, 2015 ... ... U.S. District Court for the Northern District of Ohio, Western Division (Case No. ... complaint (Case No: 3:15-cv-00397), the women experienced spontaneous migration of their Implanon® implants, ...
(Date:7/31/2015)... ... 2015 , ... The Heart Fit Clinic has increased a patient's fitness level ... of 150 beats versus 100 beats, this is a big deal," says Diamond Fernandes, ... back to patients with heart disease," he adds. People with angina are able to ...
(Date:7/31/2015)... ... 31, 2015 , ... Florida Hospital Tampa has started treating ... for targeted delivery of fluids to selected sites in the peripheral vascular system. ... with the device that provides direct, local delivery of chemotherapy to the pancreas. ...
Breaking Medicine News(10 mins):Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 3Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 3Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 2Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 3Health News:Heart Fit Clinic Helps Patient Increase Fitness Level with External Counterpulsation 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 4
... authored by two Memorial University faculty members published in ... the Public Library// of// Science (PLoS). Drs. Amin A. ... the paper, entitled, "Prevalence of depression among house holds ... the mental health policy." ,Dr. Muhammad Gadit ...
... allow a pioneering doctor, currently under house arrest in Henan ... award for her work on behalf// of HIV/AIDS patients, it ... had permission to travel," retired professor Gao Yaojie, 79, told ... holding her under house arrest for two weeks. ...
... found supporting evidence to implicate insulin-like growth factor receptor ... ,In a previous research, Terry J. Smith, M.D. and ... immunoglobulins and IGF-1R as a cause of inflammation and ... , The discovery of these mechanisms in ...
... University have developed a novel spraying method for delivering ... a new low-cost and scaleable technique that offers needle-free ... methods. The process could one day provide a better ... related spread of HIV/AIDS in the developing world. ...
... If you are cooking with garlic, crush the pods first ... benefits and medicinal properties are well known. It has long ... folklore for preventing everything from the common cold and flu ... herbal medicine and it contains compounds shown to help prevent ...
... on Friday plan to distribute 250,000 city-branded condoms as ... the spread of HIV// and other sexually transmitted infections, ... purple and yellow package is printed in English and ... Coming together to stop HIV in D.C.' The first ...
Cached Medicine News:Health News:A Single Biological Mechanism Behind Several Autoimmune Disorders 2Health News:Scientists Partner to Develop and Distribute New Tuberculosis Vaccine 2Health News:Free Condoms Distribution to Prevent HIV in Washington 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: